167 related articles for article (PubMed ID: 15899731)
1. Experience with community-based amphotericin B infusion therapy.
Malani PN; Depestel DD; Riddell J; Bickley S; Klein LR; Kauffman CA
Pharmacotherapy; 2005 May; 25(5):690-7. PubMed ID: 15899731
[TBL] [Abstract][Full Text] [Related]
2. [Amphotericin B deoxycholate prescription and adverse events in a Chilean university hospital].
Quinteros A R; Fica C A; Abusada A N; Muñoz C L; Novoa M C; Gallardo A C
Rev Chilena Infectol; 2010 Feb; 27(1):25-33. PubMed ID: 20140311
[TBL] [Abstract][Full Text] [Related]
3. Characterizing and predicting amphotericin B-associated nephrotoxicity in bone marrow or peripheral blood stem cell transplant recipients.
Gubbins PO; Penzak SR; Polston S; McConnell SA; Anaissie E
Pharmacotherapy; 2002 Aug; 22(8):961-71. PubMed ID: 12173799
[TBL] [Abstract][Full Text] [Related]
4. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations.
Cannon JP; Garey KW; Danziger LH
Pharmacotherapy; 2001 Sep; 21(9):1107-14. PubMed ID: 11560200
[TBL] [Abstract][Full Text] [Related]
5. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
Maharom P; Thamlikitkul V
J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S118-24. PubMed ID: 17718252
[TBL] [Abstract][Full Text] [Related]
6. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
Walsh TJ; Finberg RW; Arndt C; Hiemenz J; Schwartz C; Bodensteiner D; Pappas P; Seibel N; Greenberg RN; Dummer S; Schuster M; Holcenberg JS
N Engl J Med; 1999 Mar; 340(10):764-71. PubMed ID: 10072411
[TBL] [Abstract][Full Text] [Related]
7. Amphotericin B infusion-related toxicity: comparison of two- and four-hour infusions.
Nicholl TA; Nimmo CR; Shepherd JD; Phillips P; Jewesson PJ
Ann Pharmacother; 1995 Nov; 29(11):1081-7. PubMed ID: 8573948
[TBL] [Abstract][Full Text] [Related]
8. Deoxycholate amphotericin B and nephrotoxicity in the pediatric setting.
Bes DF; Rosanova MT; Sberna N; Arrizurieta E
Pediatr Infect Dis J; 2014 Aug; 33(8):e198-206. PubMed ID: 24618932
[TBL] [Abstract][Full Text] [Related]
9. Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex.
Wade RL; Chaudhari P; Natoli JL; Taylor RJ; Nathanson BH; Horn DL
Diagn Microbiol Infect Dis; 2013 Jul; 76(3):361-7. PubMed ID: 23774005
[TBL] [Abstract][Full Text] [Related]
10. Amphotericin B colloidal dispersion.
Patel R
Expert Opin Pharmacother; 2000 Mar; 1(3):475-88. PubMed ID: 11249532
[TBL] [Abstract][Full Text] [Related]
11. Single-dose liposomal amphotericin B for visceral leishmaniasis in India.
Sundar S; Chakravarty J; Agarwal D; Rai M; Murray HW
N Engl J Med; 2010 Feb; 362(6):504-12. PubMed ID: 20147716
[TBL] [Abstract][Full Text] [Related]
12. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial.
Boogaerts M; Winston DJ; Bow EJ; Garber G; Reboli AC; Schwarer AP; Novitzky N; Boehme A; Chwetzoff E; De Beule K;
Ann Intern Med; 2001 Sep; 135(6):412-22. PubMed ID: 11560454
[TBL] [Abstract][Full Text] [Related]
13. Chest discomfort associated with liposomal amphotericin B: report of three cases and review of the literature.
Johnson MD; Drew RH; Perfect JR
Pharmacotherapy; 1998; 18(5):1053-61. PubMed ID: 9758315
[TBL] [Abstract][Full Text] [Related]
14. Risk factors of amphotericin B toxicty in the nonneonatal pediatric population.
Dutta A; Palazzi DL
Pediatr Infect Dis J; 2012 Sep; 31(9):910-4. PubMed ID: 22581225
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety.
Hamill RJ; Sobel JD; El-Sadr W; Johnson PC; Graybill JR; Javaly K; Barker DE
Clin Infect Dis; 2010 Jul; 51(2):225-32. PubMed ID: 20536366
[TBL] [Abstract][Full Text] [Related]
16. Antimycotic therapy with liposomal amphotericin-B for patients undergoing bone marrow or peripheral blood stem cell transplantation.
Krüger W; Stockschläder M; Sobottka I; Betker R; De Wit M; Kröger N; Grimm J; Arland M; Fiedler W; Erttmann R; Zander AR
Leuk Lymphoma; 1997 Feb; 24(5-6):491-9. PubMed ID: 9086439
[TBL] [Abstract][Full Text] [Related]
17. Adverse effects of amphotericin B in children; a retrospective comparison of conventional and liposomal formulations.
Andrew EC; Curtis N; Coghlan B; Cranswick N; Gwee A
Br J Clin Pharmacol; 2018 May; 84(5):1006-1012. PubMed ID: 29352486
[TBL] [Abstract][Full Text] [Related]
18. Amphotericin B--not so terrible.
Bishara J; Weinberger M; Lin AY; Pitlik S
Ann Pharmacother; 2001 Mar; 35(3):308-10. PubMed ID: 11261528
[TBL] [Abstract][Full Text] [Related]
19. Safety of amphotericin B colloidal dispersion.
Herbrecht R
Eur J Clin Microbiol Infect Dis; 1997 Jan; 16(1):74-80. PubMed ID: 9063677
[TBL] [Abstract][Full Text] [Related]
20. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain.
Aguado JM; Lumbreras C; González-Vidal D;
Clin Microbiol Infect; 2004 Sep; 10(9):785-90. PubMed ID: 15355408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
